基金业绩年末冲刺战况激烈，“流量阀”调控暗藏玄机

Core Insights - The A-share market is experiencing significant structural differentiation, with a performance gap exceeding 220 percentage points between top and bottom-performing funds, highlighting a "high-cut low" characteristic [1][3] - Many fund companies are dynamically adjusting their subscription policies, with some high-performing funds lifting restrictions on large subscriptions while others are tightening limits to manage performance and scale [1][5] Market Performance - As of November 10, the A-share market is fluctuating around the 4000-point mark, with the Shanghai Composite Index showing a year-to-date increase of 19.9% [2] - The average return of actively managed equity funds has decreased from 33.08% at the end of Q3 to 30.51% [2][3] Fund Performance - Top-performing funds include Yongying Technology Smart A with a return of 205.35%, followed by Hengyue Advantage Selection at 147.36% and Hongtu Innovation Emerging Industry at 139.82% [3][4] - There are currently 147 actively managed equity funds struggling with negative returns, with some experiencing declines exceeding 10% [3] Subscription Policy Adjustments - Several funds have lifted restrictions on large subscriptions, including E Fund Rui Xiang Mixed and Changcheng Medical Industry Selection, to meet investor demand [5][6] - Conversely, 218 actively managed equity funds have suspended large subscriptions, with some limiting daily subscription amounts to as low as 100 yuan [7][8] Market Outlook - The market is expected to maintain a slow bull trend in Q4, with recommendations for balanced investment strategies across various sectors [8][9] - The innovation drug sector is facing volatility due to a mismatch between market expectations and actual industry developments, with a shift in focus from short-term event-driven trading to long-term fundamental performance [9]